Diabetes
Areas of partnering interest:
Insulins.
GLP-1 analogues.
Therapeutic proteins and peptides for:
- Symptomatic treatment of at least two of the manifestations of the metabolic syndrome (glucose regulation + obesity or lipids/atherosclerosis)
- Glucose regulation via glucose dependent mechanism
- Beta cell: Insulin secretion/resistance, beta cell regeneration/proliferation/neogenesis and/or cell therapy
- Prevention and/or intervention of Type 1, Type 2 or Type 1/2 diabetes
- Obesity
- Diabetes late complications: Late-stage discovery or development compound for microvascular complications
Diabetes Research Unit
For other enquiries
Contact
For further information please contact Diabetes Sourcing & Strategy
Download
Please download the Novo Nordisk:
Partnering folder
Diabetes folder
